Hypertension Diagnosis and Management: New findings from the recent guidelines

Document Type : Review Article

Authors

1 Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

10.30476/tips.2024.103312.1248

Abstract

Hypertension is a common disorder around the world which is mainly asymptomatic and in this regard, it is known as a silent killer disease. Hypertension can induce various complications including cardiovascular disorders i.e. heart failure, angina, and acute coronary syndrome, renal failure, cerebrovascular disease, and retinopathies, in this regard, regular screening, early diagnosis and management of hypertension is crucial. In general, angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), β-blockers, and thiazide diuretics are considered as first-line agents for hypertension management. However, selection of a suitable antihypertensive regimen is mainly affected by the patients’ specific conditions and also their comorbidities. In this review, the latest versions of different hypertension guidelines including “2023 European Society of Heart (ESH) Guidelines for the Management of Arterial Hypertension”, “2020 International Society of Hypertension Global Hypertension Practice Guidelines” and “2017 ACC/ AHA/ AAPA/ ABC/ ACPM/ AGS/ APhA/ ASH/ ASPC/ NMA/ PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults” and also recently related publications have been reviewed. Moreover, pharmacotherapy in special groups of patients and those with comorbidities have been summarized according to the latest guidelines that are currently available for each predisposing disease. Finally, hypertension crises diagnosis and management are discussed. 

Highlights

Parisa Ghasemiyeh (Google Scholar)

Soliman Mohammadi-Samani (Google Scholar)

Keywords

References

1.    Hypertension  [Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension.
2.    High Blood Pressure–Understanding the Silent Killer  [Available from: https://www.fda.gov/drugs/special-features/high-blood-pressure-understanding-silent-killer#:~:text=Your%20blood%20pressure%20is%20considered,seek%20medical%20treatment%20right%20away.
3.    Guideline for the pharmacological treatment of hypertension in adults  [Available from: https://www.who.int/publications/i/item/9789240033986.
4.    CAROLINE S. ZEIND MGC, JUDY W. CHENG, KATHY ZAIKEN, TRISHA LAPOINTE. Essential Hypertension.  APPLIED THERAPEUTICS The Clinical Use of Drugs. Philadelphia, USA.: Wolters Kluwer; 2023.
5.    Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480. 
6.    Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):1269-1324. doi: 10.1161/HYP.0000000000000066. 
7.    Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun;75(6):1334-1357. doi: 10.1161/HYPERTENSIONAHA.120.15026. 
8.    Kokubo Y, Iwashima Y, Kamide K. Hypertension: Introduction, types, causes, and complications. Pathophysiology and Pharmacotherapy of Cardiovascular Disease. 2015:635-53.
9.    Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD001841. doi: 10.1002/14651858.CD001841.pub3. PMID: 29667175; PMCID: PMC6513559.
10.    Gupta R, Maitz T, Egeler D, Mehta A, Nyaeme M, Hajra A, et al. SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure. Trends Cardiovasc Med. 2023 Nov;33(8):479-486. doi: 10.1016/j.tcm.2022.05.005. 
11.    Sawami K, Tanaka A, Node K. Recent understandings about hypertension management in type 2 diabetes: What are the roles of SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone? Hypertens Res. 2023 Aug;46(8):1892-1899. doi: 10.1038/s41440-023-01324-9. Epub 2023 May 31. PMID: 37258623.
12.    Kobayashi M, Girerd N, Zannad F. When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases. Nephrol Dial Transplant. 2024 Jun 28;39(7):1063-1072. doi: 10.1093/ndt/gfae004. PMID: 38192033.
13.    Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, et al. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. 2023;16(2):293-302.
14.    Wilcox CS. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors. Hypertension. 2020 Apr;75(4):894-901. doi: 10.1161/HYPERTENSIONAHA.119.11684. 
15.    Briasoulis A, Al Dhaybi O, Bakris GL. SGLT2 Inhibitors and Mechanisms of Hypertension. Curr Cardiol Rep. 2018 Jan 19;20(1):1. doi: 10.1007/s11886-018-0943-5. PMID: 29349558.
16.    FDA Approves Valsartan/Sacubitril (Entresto) Combination for Heart Failure  [Available from: https://www.medscape.com/viewarticle/847619?st=fpf&scode=msp&socialSite=google&form=fpf&icd=login_success_gg_match_fpf.
17.    Sousa CT, Ribeiro A, Barreto SM, Giatti L, Brant L, Lotufo P, Chor D, et al. Racial Differences in Blood Pressure Control from Users of Antihypertensive Monotherapy: Results from the ELSA-Brasil Study. Arq Bras Cardiol. 2022 Mar;118(3):614-622. English, Portuguese. doi: 10.36660/abc.20201180. 
18.    Brown CM, Garovic VD. Drug treatment of hypertension in pregnancy. Drugs. 2014 Mar;74(3):283-96. doi: 10.1007/s40265-014-0187-7. 
19.    Stephens MM, Fox BA, Maxwell L. Therapeutic options for the treatment of hypertension in children and adolescents. Clin Med Insights Circ Respir Pulm Med. 2012;6:13-25. doi: 10.4137/CCRPM.S7602. 
20.    Burrello J, Erhardt EM, Saint-Hilary G, Veglio F, Rabbia F, Mulatero P, et al. Pharmacological Treatment of Arterial Hypertension in Children and Adolescents: A Network Meta-Analysis. Hypertension. 2018 Aug;72(2):306-313. doi: 10.1161/HYPERTENSIONAHA.118.10862. 
21.    Tan JL, Thakur K. Systolic Hypertension. 2023 Jan 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 29494079.
22.    Değirmenci H, Bakirci EM, Çakir M, Tanrıseven Hİ. Current approach to isolated diastolic hypertension. Arch Clin Hypertens. 2020;6(1):029-31.
23.    JNC 8 Guidelines for the Management of Hypertension in Adults  [Available from: https://www.aafp.org/pubs/afp/issues/2014/1001/p503.html.
24.    American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S179-S218. doi: 10.2337/dc24-S010. PMID: 38078592; PMCID: PMC10725811.
25.    Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney international. 2024;105(4):S117-S314. DOI: 10.1016/j.kint.2023.10.018
26.    Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29;148(9):e9-e119. doi: 10.1161/CIR.0000000000001168. 
27.    Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E. Role of spironolactone in the treatment of heart failure with preserved ejection fraction. Ann Transl Med. 2018 Dec;6(23):461. doi: 10.21037/atm.2018.11.16. 
28.    Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. 
29.    Kommu S, Berg RL. The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2024 Mar 9;13(6):1572. doi: 10.3390/jcm13061572. PMID: 38541798; PMCID: PMC10971386.
30.    Wei FF, Zhang ZY, Huang QF, Staessen JA. Diagnosis and management of resistant hypertension: state of the art. Nat Rev Nephrol. 2018 Jul;14(7):428-441. doi: 10.1038/s41581-018-0006-6. PMID: 29700488.
31.    Schiffrin EL, Fisher NDL. Diagnosis and management of resistant hypertension. BMJ. 2024 Jun 19;385:e079108. doi: 10.1136/bmj-2023-079108. Erratum in: BMJ. 2024 Jun 27;385:q1430. doi: 10.1136/bmj.q1430. PMID: 38897628.
32.    M. G. C. CAROLINE S. ZEIND JWC, KATHY ZAIKEN, TRISHA LAPOINTE. Hypertensive Crises.  APPLIED THERAPEUTICS The Clinical Use of Drugs. Philadelphia, USA.: Wolters Kluwer; 2023.
33.    Salvador VD, Bakris GL. Novel antihypertensive agents for resistant hypertension: what does the future hold? Hypertens Res. 2022 Dec;45(12):1918-1928. doi: 10.1038/s41440-022-01025-9. Epub 2022 Sep 27. PMID: 36167808.
34.    Blazek O, Bakris GL. Novel Therapies on the Horizon of Hypertension Management. Am J Hypertens. 2023 Feb 13;36(2):73-81. doi: 10.1093/ajh/hpac111. PMID: 36201204.
Trends in Pharmaceutical Sciences
Volume 10, Issue 3
September 2024
Pages 185-204

Files

Share

How to cite

Statistics